Vitality Watch

Dossier pubmed preclinical 01-oct-2026
Animal model, organoid, or cell-culture result — not yet human

Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.

Briefing card

Novel Flavonoid Senotherapeutics Identified by Phenotypic Drug Discovery Reduce Senescence and Improve Multiple Markers of Healthspan.
Stage: preclinical · pubmed · 01-oct-2026

If you are tracking fisetin as the senolytic flavonoid, note that newer fisetin-derived analogs outperform it in mice — the human trials still underway are testing the weakest member of the family.

Novel fisetin-derived flavonoid senolytics SR29384 and SR31133 show enhanced senolytic activity across senescent cell types, reduce tissue senescence, and improve multiple healthspan markers in aging mouse models.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1111/acel.70736

build build 880 · 2bcef25 · 2026-11-18